Recent Press Releases
Cernostics Contracts with Geisinger Health Plan to Become an In-network Provider for TissueCypher® Barrett’s Esophagus Assay
Cernostics, pioneer of the worlds’ first precision medicine test to predict future development risk of esophageal cancer from Barrett’s esophagus (BE), TissueCypher® Barrett’s Esophagus Assay, has become a participating (“in-network”) provider for Geisinger Health Plan (GHP)’s more than 550,000 plan members in Central, North Central and East Central Pennsylvania. Read More
Digestive Disease Week® 2021 to Showcase the TissueCypher® Barrett’s Esophagus Assay as a Paradigm-shifting Precision Medicine Tool
Mayo Clinic and AMC Amsterdam to Pr Read More
Recent Media Coverage
Pittsburgh Life Sciences Greenhouse Proudly Announces Portfolio Company Cernostics is Being Acquired by Castle Biosciences
Pittsburgh Life Science Greenhouse Read More
Cernostics CEO on the opportunities ahead with Castle’s acquisition
Cernostics CEO Michael Hoerres said Read More
Research Validates Tissue Pathology Test Predicting Progression in Barrett’s Esophagus
Objective risk assessment guides su Read More